Sort:
Open Access Original Article Issue
The Burden of Breast Cancer and its Attributable Risk Factors in 204 Countries and Territories, 1990–2021: Results From the Global Burden of Disease Study 2021
Cancer Innovation 2026, 5(2): e70055
Published: 10 April 2026
Abstract PDF (2.9 MB) Collect
Downloads:135
Background

To report the global, regional, and national burden of breast cancer (BC) and its attributable risk factors between 1990 and 2021, by age, sex, and sociodemographic index.

Methods

Using data from the Global Burden of Disease Study 2021, we analyzed BC prevalence, deaths, disability‐adjusted life years (DALYs), and attributable risk factors across 204 countries and territories from 1990 to 2021. Age‐standardized prevalence, deaths, and DALYs rates were estimated, and temporal trends were assessed using the estimated annual percentage change. Geographical and sociodemographic inequalities were further evaluated using decomposition analysis, concentration curves, and sociodemographic index (SDI)‐based modeling. Attributable risk factors for deaths and DALYs were quantified using the comparative risk assessment framework.

Results

Globally, BC presents a starkly diverging landscape. While the age‐standardized prevalence has climbed to 239 per 100,000 (a 9.3% increase since 1990), the death and DALYs rates have actually declined by 13.7% and 9.8%, respectively. This global trend, however, masks a critical geographical shift. High‐income regions maintain the highest prevalence, yet the most rapid increases in burden are now concentrated in resource‐limited areas such as North Africa and the Middle East. The “triple threat” in low‐SDI regions defines this transition. Decomposition analysis revealed that while population growth and aging lead to absolute mortality everywhere, high‐SDI regions successfully offset this pressure through favorable epidemiological changes and advancements in screening and treatment. In contrast, low‐SDI regions face a deteriorating epidemiological profile that actively contributes to rising deaths. Our inequality analysis further underscores this systemic shift; concentration curves confirm that BC mortality is becoming disproportionately concentrated in lower‐SDI countries over time. Additionally, the disease follows a nonlinear, inverted U‐shaped relationship with socioeconomic development, peaking at an SDI of 0.75. Finally, we identified a distinct sex‐based etiological divide: while female risk patterns are multifaceted, male BC is almost singularly driven by metabolic dysregulation, with high body mass index emerging as the leading global driver of the disease.

Conclusions

Despite progress in reducing the BC burden, it remains a global public health challenge. The prevalence is high in developed countries, while the burden is rapidly increasing in low‐ and middle‐income countries.

Open Access Review Issue
Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer
Cancer Innovation 2026, 5(1): e70043
Published: 05 March 2026
Abstract PDF (1.6 MB) Collect
Downloads:55

In recent years, multidisciplinary treatment strategies have profoundly improved drug responses and survival outcomes of breast cancer (BC) patients. However, there is an urgent need for novel therapies for BC patients who are heavily treated or develop resistance to conventional treatment regimens. Radionuclide therapy (RT) and targeted radionuclide therapy (TRT) have emerged as paradigm‐shifting therapeutic approaches for BC, which enable functions of both imaging and localised treatment. They utilise radionuclides that can selectively bind to biomarkers overexpressing on BC cells, allowing precise delivery and localised tumour irradiation. Moreover, several types of radionuclides possess ‘cross‐fire’ effects that result in the eradication of neighbouring tumour cells lacking the biomarker expression. In the current review, we summarise the potential biomarkers for the development of RT and TRT that can be employed in the treatment of BC, including receptor markers of ER, PR and HER2, together with other markers of Trop2, PD‐1, EGFR, GRPR and PSMA.

Total 2